All In Biotech

Drug Trial Radar · NCT05578976

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compared to R-CHOP in Subjects With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 900 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

900

Planned (sponsor's estimate)

Start

Feb 8, 2023

Primary completion

Jun 2027

Study completion Dec 2029

Sponsor

Lead sponsor
GenmabIndustry
Sponsor type
Industry
First posted
Oct 13, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). The purpose of this study is to assess the change in disease activity of epcoritamab when combined with intravenous and oral rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP) or R-CHOP in adult participants globally with diffuse large b-cell lymphoma (DLBCL). Change in disease activity will be assessed. Epcoritamab is an investigational drug being developed for the treatment of DLBCL. Study doctors put the participants in groups called treatment arms. Participants will receive epcoritamab combined with R-CHOP, followed by epcoritamab or R-CHOP followed by rituximab will be explored. Approximately 900 adult participants with with newly diagnosed DLBCL will be enrolled in the study in approximately 315 sites in globally. In the Arm 1, participants will receive subcutaneous epcoritamab combined with intravenous and oral R-CHOP followed by subcutaneous epcoritamab in 21-day cycles. In the Arm 2, participants will receive intravenous and oral R-CHOP followed by intravenous rituximab in 21-day cycles. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

Conditions

  • Diffuse Large B-Cell Lymphoma

Interventions

  • EpcoritamabDrug

    Subcutaneous Injection (SC)

  • CyclophosphamideDrug

    Intravenous (IV) Injection

  • RituximabDrug

    IV Infusion

  • VincristineDrug

    IV Infusion

  • DoxorubicinDrug

    IV Infusion

  • PrednisoneDrug

    Oral; Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Progression-Free Survival (PFS) with an International Prognostic Index (IPI) of 3-5Time frame: Up to Approximately 46 Months

Locations

331 sites in 31 countries. Site status is shown where the registry gives one.

  • Duplicate_University of Arizona Cancer Center - North Campus /ID# 227463

    Tucson, Arizona

  • Yuma Regional Medical Center Cancer Center /ID# 261527

    Yuma, Arizona

  • University of Arkansas for Medical Sciences /ID# 225703

    Little Rock, Arkansas

  • CBCC Global Research, Inc. /ID# 262037

    Bakersfield, California

  • Alta Bates Summit Medical Center for Research /ID# 229427

    Berkeley, California

  • Orange Coast Memorial Medical Center /ID# 229632

    Fountain Valley, California

  • Providence - St. Jude Medical Center /ID# 262042

    Fullerton, California

  • Saddleback Memorial Medical Center /ID# 229631

    Laguna Hills, California

  • Long Beach Memorial Medical Ct /ID# 228996

    Long Beach, California

  • Cancer and Blood Speciality Clinic - Los Alamitos /ID# 262032

    Los Alamitos, California

  • University of Southern California /ID# 225443

    Los Angeles, California

  • University of California, Los Angeles /ID# 226887

    Los Angeles, California

  • Kaiser Permanente, Waterpark III Institute for Health Research /ID# 228618

    Aurora, Colorado

  • Duplicate_Cancer Specialists of North Florida /ID# 226826

    Jacksonville, Florida

  • Ocala Oncology Florida Cancer Affiliates - Main /ID# 262785

    Ocala, Florida

  • Orlando Health Cancer Institute /ID# 232626

    Orlando, Florida

  • Straub Medical Center /ID# 229464

    Honolulu, Hawaii

  • University of Illinois at Chicago /ID# 226889

    Chicago, Illinois

  • Southern IL Univ School of Med /ID# 228999

    Springfield, Illinois

  • Springfield Clinic Main Campus /ID# 262584

    Springfield, Illinois

  • Carle Cancer Institute /ID# 228338

    Urbana, Illinois

  • Parkview Comprehensive Cancer Center /ID# 227026

    Fort Wayne, Indiana

  • Goshen Center for Cancer Care /ID# 225534

    Goshen, Indiana

  • University of Iowa Health Care /ID# 261945

    Des Moines, Iowa

  • Cancer Center of Kansas /ID# 261983

    Wichita, Kansas

  • Norton Cancer Institute - St. Matthews /ID# 225420

    Louisville, Kentucky

  • University of Maryland, Baltimore /ID# 225421

    Baltimore, Maryland

  • Johns Hopkins Hospital /ID# 225369

    Baltimore, Maryland

  • American Oncology Partners of Maryland /ID# 226859

    Bethesda, Maryland

  • UMass Memorial Medical Center /ID# 226939

    Worcester, Massachusetts

  • University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 225462

    Ann Arbor, Michigan

  • Trinity Health St. Joseph Mercy Ann Arbor /ID# 228206

    Ypsilanti, Michigan

  • Metro Minnesota Community Oncology Research Consortium (MMCORC) /ID# 226680

    Saint Louis Park, Minnesota

  • University of Mississippi Medical Center /ID# 228045

    Jackson, Mississippi

  • Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana /ID# 259014

    Billings, Montana

  • NHO Revive Research Institute, LLC /ID# 261113

    Lincoln, Nebraska

  • MDACC Cooper /ID# 260320

    Camden, New Jersey

  • Titan Health Partners LLC, d/b/a Astera Cancer Care /ID# 226654

    East Brunswick, New Jersey

  • Morristown Medical Center /ID# 239457

    Morristown, New Jersey

  • University of New Mexico /ID# 227332

    Albuquerque, New Mexico

Showing 40 of 331 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.